Elicio Therapeutics initiated with a Buy at JonesResearch
The Fly

Elicio Therapeutics initiated with a Buy at JonesResearch

JonesResearch analyst Soumit Roy initiated coverage of Elicio Therapeutics (ELTX) with a Buy rating and $9 price target Elicio’s off-the-shelf cancer vaccine candidate is “probably given the best possible chance to succeed,” the analyst tells investors in a research note. The firm says the company’s AMP platform delivers neoantigen peptides to the lymph nodes to generate better immune response, a hot tumor type in post-surgical setting but with biomarker positive status.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App